Pain & Reward Neuromodulation of CNS Circuits
Part of paid clinical trials in Durham, North Carolina.
- Sponsor
- Duke University
- Study ID
- NCT07525063
- Status
- Enrolling By Invitation
Conditions
- Chronic Pain and Fatigue
- Fibromyalgia
- Fibromyalgia Syndrome
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Transcranial Magnetic Stimulation (TMS) — DEVICETMS protocol delivered via MagPro X100 stimulator with figure-8 coil targeting prefrontal cortex.
Study Details
This pilot feasibility study aims to evaluate transcranial magnetic stimulation (TMS) targeting the prefrontal cortex in patients with fibromyalgia syndrome (FMS). The study will assess preliminary efficacy and mechanisms of central nervous system changes using neuroimaging, behavioral tasks, sensory testing, and neuroimmune markers. Participants will undergo MRI scans, multi-day TMS sessions, and complete questionnaires. The goal is to generate pilot data for future trials on neuromodulation for chronic pain.
Key Dates
- First listed
- Apr 13, 2026
- Start date
- Jul 21, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Active TMSParticipants receive TMS over 4 consecutive days (20 sessions total).
Primary Outcome Measure
Change in Pain Intensity [ Time Frame: Baseline MRI and post-intervention MRI (approximately 3 weeks) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | - |
Find similar trials in Durham, NC
By research site
Related Studies
- Neural Mechanisms of Light Driven AnalgesiaRecruiting · University of North Carolina, Chapel Hill · Chapel Hill, North Carolina
- Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignPHASE3 · Recruiting · Axsome Therapeutics, Inc. · Glendale, Arizona
- Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.PHASE1 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- taVNS Treatment for FibromyalgiaNot Yet Recruiting · Massachusetts General Hospital · Charlestown, Massachusetts